References
1. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2015; 192: 134-156.
2. Hysinger E, Friedman N, Jensen E, Zhang H, Piccione J. Bronchoscopy in neonates with severe bronchopulmonary dysplasia in the NICU. J Perinatol 2019; 39: 263-268.
3. Doyle LW, Carse E, Adams AM, Ranganathan S, Opie G, Cheong JLY. Ventilation in Extremely Preterm Infants and Respiratory Function at 8 Years. N Engl J Med 2017; 377: 329-337.
4. Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks’ gestational age.Pediatrics 2010; 126: 115-128.
5. Di Fiore JM, Dylag AM, Honomichl RD, Hibbs AM, Martin RJ, Tatsuoka C, Raffay TM. Early inspired oxygen and intermittent hypoxemic events in extremely premature infants are associated with asthma medication use at 2 years of age. J Perinatol 2019; 39: 203-211.
6. Wang H, Jafri A, Martin RJ, Nnanabu J, Farver C, Prakash YS, MacFarlane PM. Severity of neonatal hyperoxia determines structural and functional changes in developing mouse airway. Am J Physiol Lung Cell Mol Physiol 2014; 307: L295-301.
7. Dylag AM, Mayer CA, Raffay TM, Martin RJ, Jafri A, MacFarlane PM. Long-term effects of recurrent intermittent hypoxia and hyperoxia on respiratory system mechanics in neonatal mice. Pediatr Res 2017; 81: 565-571.
8. Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol 2017; 140: 895-906.
9. Cui TX, Maheshwer B, Hong JY, Goldsmith AM, Bentley JK, Popova AP. Hyperoxic Exposure of Immature Mice Increases the Inflammatory Response to Subsequent Rhinovirus Infection: Association with Danger Signals.J Immunol 2016; 196: 4692-4705.
10. Pryhuber GS. Postnatal Infections and Immunology Affecting Chronic Lung Disease of Prematurity. Clin Perinatol 2015; 42: 697-718.
11. Scheible KM, Emo J, Laniewski N, Baran AM, Peterson DR, Holden-Wiltse J, Bandyopadhyay S, Straw AG, Huyck H, Ashton JM, Tripi KS, Arul K, Werner E, Scalise T, Maffett D, Caserta M, Ryan RM, Reynolds AM, Ren CL, Topham DJ, Mariani TJ, Pryhuber GS. T cell developmental arrest in former premature infants increases risk of respiratory morbidity later in infancy. JCI Insight 2018; 3.
12. Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, Cnaan A, Palermo L, Wadlinger SR, Coburn CE, Ballard PL, Ballard RA. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. J Pediatr 2008; 153: 525-529.
13. Moreno-Galdó A, Pérez-Yarza EG, Ramilo O, Rubí T, Escribano A, Torres A, Sardón O, Oliva C, Pérez G, Cortell I, Rovira-Amigo S, Pastor-Vivero MD, Pérez-Frías J, Velasco V, Torres J, Figuerola J, Barrio MI, García-Hernández G, Mejías A. Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants. Pediatr Allergy Immunol 2020; 31: 124-132.
14. Proietti E, Riedel T, Fuchs O, Pramana I, Singer F, Schmidt A, Kuehni C, Latzin P, Frey U. Can infant lung function predict respiratory morbidity during the first year of life in preterm infants? Eur Respir J 2014; 43: 1642-1651.
15. Stevens TP, Finer NN, Carlo WA, Szilagyi PG, Phelps DL, Walsh MC, Gantz MG, Laptook AR, Yoder BA, Faix RG, Newman JE, Das A, Do BT, Schibler K, Rich W, Newman NS, Ehrenkranz RA, Peralta-Carcelen M, Vohr BR, Wilson-Costello DE, Yolton K, Heyne RJ, Evans PW, Vaucher YE, Adams-Chapman I, McGowan EC, Bodnar A, Pappas A, Hintz SR, Acarregui MJ, Fuller J, Goldstein RF, Bauer CR, O’Shea TM, Myers GJ, Higgins RD. Respiratory outcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT). J Pediatr 2014; 165: 240-249.e244.
16. Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, Thomas S, Stocks J. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010; 182: 237-245.
17. Hacking DF, Gibson AM, Robertson C, Doyle LW. Respiratory function at age 8-9 after extremely low birthweight or preterm birth in Victoria in 1997. Pediatr Pulmonol 2013; 48: 449-455.
18. Hennessy EM, Bracewell MA, Wood N, Wolke D, Costeloe K, Gibson A, Marlow N. Respiratory health in pre-school and school age children following extremely preterm birth. Arch Dis Child 2008; 93: 1037-1043.
19. Kotecha SJ, Watkins WJ, Lowe J, Granell R, Henderson AJ, Kotecha S. Comparison of the Associations of Early-Life Factors on Wheezing Phenotypes in Preterm-Born Children and Term-Born Children. Am J Epidemiol 2019; 188: 527-536.
20. Morata-Alba J, Romero-Rubio MT, Castillo-Corullón S, Escribano-Montaner A. Respiratory morbidity, atopy and asthma at school age in preterm infants aged 32-35 weeks. Eur J Pediatr 2019; 178: 973-982.
21. Vrijlandt E, Reijneveld SA, Aris-Meijer JL, Bos AF. Respiratory Health in Adolescents Born Moderately-Late Preterm in a Community-Based Cohort. J Pediatr 2018; 203: 429-436.
22. Yaacoby-Bianu K, Plonsky MT, Gur M, Bar-Yoseph R, Kugelman A, Bentur L. Effect of late preterm birth on lung clearance index and respiratory physiology in school-age children. Pediatr Pulmonol 2019; 54: 1250-1256.
23. Dylag AM, Kopin HG, O’Reilly MA, Wang H, Davis SD, Ren CL, Pryhuber GS. Early Neonatal Oxygen Exposure Predicts Pulmonary Morbidity and Functional Deficits at 1 Year. J Pediatr 2020; 223: 20-28.e22.
24. Keller RL, Feng R, DeMauro SB, Ferkol T, Hardie W, Rogers EE, Stevens TP, Voynow JA, Bellamy SL, Shaw PA, Moore PE. Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study. J Pediatr 2017; 187: 89-97.e83.
25. Håland G, Carlsen KCL, Sandvik L, Devulapalli CS, Munthe-Kaas MC, Pettersen M. Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 2006; 355.
26. Martinez FD, Morgan WJ, Wright AL, Holberg C, Taussig LM. Initial airway function is a risk factor for recurrent wheezing respiratory illnesses during the first three years of life. Group Health Medical Associates. Am Rev Respir Dis 1991; 143.
27. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988; 319.
28. Bentsen MH, Markestad T, Øymar K, Halvorsen T. Lung function at term in extremely preterm-born infants: a regional prospective cohort study.BMJ Open 2017; 7: e016868.
29. Ren CL, Feng R, Davis SD, Eichenwald E, Jobe A, Moore PE, Panitch HB, Sharp JK, Kisling J, Clem C, Kemp JS. Tidal Breathing Measurements at Discharge and Clinical Outcomes in Extremely Low Gestational Age Neonates. Ann Am Thorac Soc 2018; 15: 1311-1319.
30. Keller RL, Eichenwald EC, Hibbs AM, Rogers EE, Wai KC, Black DM, Ballard PL, Asselin JM, Truog WE, Merrill JD, Mammel MC, Steinhorn RH, Ryan RM, Durand DJ, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, Helderman J, Porta NF, Wadhawan R, Palermo L, Ballard RA. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. J Pediatr 2017; 183: 19-25.e12.
31. Jackson WM, O’Shea TM, Allred EN, Laughon MM, Gower WA, Leviton A. Risk factors for chronic lung disease and asthma differ among children born extremely preterm. Pediatr Pulmonol 2018; 53: 1533-1540.
32. Amitai N, Stafler P, Blau H, Kaplan E, Mussaffi H, Levine H, Steuer G, Bar-Yishay E, Klinger G, Mei-Zahav M, Prais D. Palivizumab Following Extremely Premature Birth Does Not Affect Pulmonary Outcomes in Adolescence. Chest 2020; 158: 660-669.
33. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368: 1791-1799.
34. Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EAF. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. Am J Respir Crit Care Med2017; 196: 29-38.
35. Prais D, Kaplan E, Klinger G, Mussaffi H, Mei-Zahav M, Bar-Yishay E, Stafler P, Steuer G, Sirota L, Blau H. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.Chest 2016; 149: 801-808.
36. Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol 2010; 126: 256-262.
37. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151: 34-42, 42.e31.
38. Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002; 112: 627-633.
39. Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics 2013; 132: 811-818.
40. Ryan RM, Keller RL, Poindexter BB, D’Angio CT, Shaw PA, Bellamy SL, Moore PE, McPherson C, Greenberg JM. Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. J Pediatr2019; 208: 148-155.e143.
41. Baraldi E, Bonetto G, Zacchello F, Filippone M. Low exhaled nitric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit Care Med 2005; 171: 68-72.
42. Mieskonen ST, Malmberg LP, Kari MA, Pelkonen AS, Turpeinen MT, Hallman NM, Sovijärvi AR. Exhaled nitric oxide at school age in prematurely born infants with neonatal chronic lung disease.Pediatr Pulmonol 2002; 33: 347-355.
43. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990; 9: 170-176.
44. Kao LC, Durand DJ, Nickerson BG. Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989; 6: 74-80.
45. Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants.Arch Dis Child 1990; 65: 782-785.
46. Kotecha SJ, Edwards MO, Watkins WJ, Lowe J, Henderson AJ, Kotecha S. Effect of bronchodilators on forced expiratory volume in 1 s in preterm-born participants aged 5 and over: a systematic review.Neonatology 2015; 107: 231-240.
47. Beresford MW, Primhak R, Subhedar NV, Shaw NJ. Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002; 87: F62-63.
48. Kugelman A, Peniakov M, Zangen S, Shiff Y, Riskin A, Iofe A, Shoris I, Bader D, Arnon S. Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study. J Perinatol 2017; 37: 197-202.
49. Pelkonen AS, Hakulinen AL, Hallman M, Turpeinen M. Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm.Respir Med 2001; 95: 565-570.
50. Yuksel B, Greenough A. Randomised trial of inhaled steroids in preterm infants with respiratory symptoms at follow up. Thorax1992; 47: 910-913.
51. Kao LC, Warburton D, Cheng MH, Cedeno C, Platzker AC, Keens TG. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics 1984; 74: 37-44.
52. Pacifici GM. Clinical pharmacology of furosemide in neonates: a review. Pharmaceuticals (Basel) 2013; 6: 1094-1129.